[go: up one dir, main page]

MX2007003158A - Forma cristalina 2 del clorhidrato de atrasentan. - Google Patents

Forma cristalina 2 del clorhidrato de atrasentan.

Info

Publication number
MX2007003158A
MX2007003158A MX2007003158A MX2007003158A MX2007003158A MX 2007003158 A MX2007003158 A MX 2007003158A MX 2007003158 A MX2007003158 A MX 2007003158A MX 2007003158 A MX2007003158 A MX 2007003158A MX 2007003158 A MX2007003158 A MX 2007003158A
Authority
MX
Mexico
Prior art keywords
crystalline form
atrasentan hydrochloride
atrasentan
hydrochloride
inhibition
Prior art date
Application number
MX2007003158A
Other languages
English (en)
Inventor
Geoff G Zhang
Walter Dziki
Ziqi Lu
Michael W Rasmussen
Jaqueline Wardrop
Mark Goldstein
Cathie L Linton
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MX2007003158A publication Critical patent/MX2007003158A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invencion se refiere a la forma cristalina 2 del clorhidrato de atrasentan, a composiciones que la contienen, y a metodos de tratamiento de enfermedades e inhibicion de reacciones fisiologicas adversas, utilizandola.
MX2007003158A 2004-09-17 2005-09-19 Forma cristalina 2 del clorhidrato de atrasentan. MX2007003158A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61112804P 2004-09-17 2004-09-17
PCT/US2005/033265 WO2006034084A1 (en) 2004-09-17 2005-09-19 Crystalline form 2 of atrasentan hydrochloride

Publications (1)

Publication Number Publication Date
MX2007003158A true MX2007003158A (es) 2007-05-15

Family

ID=35501053

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007003158A MX2007003158A (es) 2004-09-17 2005-09-19 Forma cristalina 2 del clorhidrato de atrasentan.

Country Status (7)

Country Link
US (1) US20060063825A1 (es)
EP (1) EP1802610A1 (es)
JP (1) JP2008513481A (es)
CA (1) CA2578824A1 (es)
MX (1) MX2007003158A (es)
TW (1) TW200626141A (es)
WO (1) WO2006034084A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006034234A1 (en) * 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form 3 of atrasentan hydrochloride
US20080132710A1 (en) * 2006-12-04 2008-06-05 Abbott Laboratories Atrasentan hydrochloride crystalline form 2
EP2190433A2 (en) 2007-08-22 2010-06-02 Gilead Colorado, Inc. Therapy for complications of diabetes
WO2014179453A1 (en) 2013-04-30 2014-11-06 Abbvie, Inc. Methods for improving lipid profiles using atrasentan
SG11201600107RA (en) 2013-07-08 2016-02-26 Abbvie Inc Stabilized pharmaceutical dosage forms comprising atrasentan
US8962675B1 (en) 2013-09-12 2015-02-24 Abbvie Inc. Atrasentan mandelate salts
CN116327758A (zh) 2019-12-17 2023-06-27 奇努克医疗公司 用阿曲生坦治疗IgA肾病的方法
EP4608396A1 (en) 2022-10-28 2025-09-03 Chinook Therapeutics, Inc. Treatment of iga nephropathy using an endothelin receptor antagonist and an april binding antibody

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002017912A1 (en) * 2000-08-31 2002-03-07 Abbott Laboratories Endothelin antagonists

Also Published As

Publication number Publication date
JP2008513481A (ja) 2008-05-01
US20060063825A1 (en) 2006-03-23
WO2006034084A1 (en) 2006-03-30
CA2578824A1 (en) 2006-03-30
TW200626141A (en) 2006-08-01
EP1802610A1 (en) 2007-07-04

Similar Documents

Publication Publication Date Title
NO2020031I1 (no) kobimetinib, inklusive farmasøytisk akseptable salter og solvater, særlig kobimetinib hemifumarat
TW200609227A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
GB0223040D0 (en) Therapeutic compounds
WO2005013892A3 (en) Hydrolytically-resistant boron-containing therapeutics and methods of use
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
MXPA05013977A (es) Metodos y composiciones para tratar enfermedades relacionadas con amiloide.
MXPA05007181A (es) Cristales de la hormona de crecimiento humano y metodos para prepararlos.
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
TW200633980A (en) Pyridones useful as inhibitors of kinases
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
TW200626068A (en) Active compounds for seed treatment
MX2007004111A (es) Sal y formas cristalinas de la misma de un farmaco.
TW200510317A (en) Caspase inhibitors and uses thereof
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
MX2007013624A (es) Inhibidores de proteina cinasa.
BRPI0416030A (pt) pirido-7-pirimidin-7-onas substituìdas com hidroxialquila
PL371281A1 (en) Methods and compositions for the treatment of eye diseases
MX2007003158A (es) Forma cristalina 2 del clorhidrato de atrasentan.
MXPA05013226A (es) Carbamatos de piperidina sustituidos, para el uso como inhibidores de la lipasa sensible a hormonas.
MY156691A (en) 2-(r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline from 1

Legal Events

Date Code Title Description
FA Abandonment or withdrawal